Overview

Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer

Status:
Active, not recruiting

Trial end date:
2021-11-30

Target enrollment:

Participant gender:

Summary

This randomized phase II/III trial studies how well netupitant and palonosetron hydrochloride works in preventing chronic nausea and vomiting in patients with cancer. Netupitant and palonosetron hydrochloride may reduce nausea and vomiting.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborators:

Helsinn Healthcare SA
National Cancer Institute (NCI)

Treatments:

Palonosetron